Brad Glick, DO, MPH

In this interview from AAD 2026, Glick speaks about key insights on topical steroid withdrawal (TSW) and on the future of dermatology.

This Q&A interview from AAD 2026 covers a number of notable tips for clinicians in dermatology regarding topical therapies.

This Q&A interview at AAD 2026 highlights a number of notable tips for clinicians in dermatology from the ‘Pearls: Diagnostic and Therapeutic’ talk.

In this Q&A discussion, Glick highlights several important points about topical steroid withdrawal and atopic dermatitis.

Brad Glick, DO, MPH; Mona Shahriari, MD, FAAD; Michael Cameron, MD, FAAD; and Linda Stein Gold, MD, comment on the future of plaque psoriasis treatment and share clinical pearls on the management of plaque psoriasis.

Expert dermatologists comment on the use of nonsteroidal topical therapies in the treatment of plaque psoriasis and how it has affected clinical practice.

Experts discuss the DERMIS clinical trials of roflumilast in the treatment of plaque psoriasis, highlighting its efficacy in the intertriginous areas.

Mona Shahriari, MD, and Linda Stein Gold, MD, review the long-term safety and efficacy data of tapinarof as well as its use in clinical practice for the management of plaque psoriasis.

Experts in dermatology discuss recent advances in the plaque psoriasis treatment toolbox, highlighting the mechanism of action and data of tapinarof.

Mona Shahriari, MD, reviews the efficacy data of topical treatments in the treatment of plaque psoriasis, and Linda Stein Gold, MD, discusses unmet needs in the plaque psoriasis treatment landscape.

Experts share the difference between the remittive and the suppressive effect in plaque psoriasis and how to get patients there.

Expert dermatologists discuss plaque psoriasis in difficult-to-treat areas such as skin folds and the face, highlighting which types of treatments they recommend.

Linda Stein Gold, MD; Mona Shahriari, MD; and Michael Cameron, MD, FAAD, share approaches to choosing between systemic and topical therapies or combination therapies to treat plaque psoriasis.

Experts discuss the current standard of care for patients with moderate-to-severe plaque psoriasis, focusing on whether the patient is a candidate for systemic or topical treatment.

Expert dermatologists provide an overview of the current topical, oral, and biologic medications available to treat plaque psoriasis.

Linda Stein Gold, MD, and Mona Shahriari, MD, comment on the psychological impact plaque psoriasis has on patients, garnering an increased risk of anxiety and depression.

Brad Glick, MD; Mona Shahriari, MD, FAAD; Michael Cameron, MD, FAAD; and Linda Stein Gold, MD, provide an overview of plaque psoriasis, highlighting demographics and risk factors, as well as the pathophysiology of the disease.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, look to the future at what is upcoming in the treatment pipeline for plaque psoriasis treatment.

Dermatology experts discuss looking ahead at clinical trial metrics and how to make different outcomes more highlighted to overcome challenges in plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss treating older populations and skin of color patients with plaque psoriasis.

Dermatology experts discuss BMI and other background comorbidities that can impact IL-23 inhibitors when treating plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss year long term efficacy and safety data regarding the use of IL-23 inhibitors in patients with moderate to severe plaque psoriasis.

Dermatology experts discuss how IL-23 inhibitors fit into the current treatment landscape for plaque psoriasis.

George Han, MD, PhD, provides an overview of the long-term persistence of different biologic treatment options for plaque psoriasis.

Neal Bhatia, MD, discusses the impact of treatment mode of delivery on patient adherence and treatment selection for IL-23 inhibitors for plaque psoriasis.

Dermatology experts provide an overview of tildrakizumab, guselkumab, and risankizumab, agents approved for patients with plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss communicating with patients about their plaque psoriasis treatment options.

George Han, MD, PhD, discusses the practical considerations of escalating treatment to the use of traditional oral systemic agents such as apremilast or methotrexate.

Neal Bhatia, MD, provides an overview of the spectrum of disease, topical choices, and transitioning to oral medications for the treatment of plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss the current role of topical therapy and the use of non-biologic oral systemic and standard therapies for plaque psoriasis treatment.